Cromos Pharma has published a white paper that gives a comprehensive overview of clinical trial landscape in the Republic of Georgia, which is becoming a very attractive location for clinical trials

09 November 2016

In addition to lightning-fast startup times, robust enrollment and full compliance with the ICH-GCP you will also be pleasantly surprised by the high quality of the study data evidenced by 12 recent 100% NAI (No Action Indicated) reports from FDA inspections.

Please follow the link to the whitepaper that may provide some additional insight into this issue.

Back to the news